Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22748702 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
Conditions: Psoriasis;   Plaque-type Psoriasis
Interventions: Drug: Apremilast 10mg;   Drug: Apremilast 20mg;   Drug: Apremilast 30 mg;   Drug: Placebo;   Drug: Apremilast 30mg

Indicates status has not been verified in more than two years